Evidence map›Paper›PMID 36077261›Full record

ArticleInternational journal of molecular sciences2022

Selenoprotein P Concentrations in the Cerebrospinal Fluid and Serum of Individuals Affected by Amyotrophic Lateral Sclerosis, Mild Cognitive Impairment and Alzheimer's Dementia.

Teresa Urbano, Marco Vinceti, Jessica Mandrioli, Annalisa Chiari, Tommaso Filippini, Roberta Bedin, Manuela Tondelli, Cecilia Simonini, Giovanna Zamboni, Misaki Shimizu and 1 more

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
2.9field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 27 citations in OpenAlex.

  1. Review
  2. Proteomic biomarkers of cognitive function,medRxiv : the preprint server for health sciences · 2026
    Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Deciphering the Role of Selenoprotein M.Antioxidants (Basel, Switzerland) · 2023
    Review
  14. Article
  15. Article
  16. Article
  17. Molecular Research on Amyotrophic Lateral Sclerosis.International journal of molecular sciences · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 3 countries.

Teresa UrbanoCREAGEN-Environmental, Genetic and Nutritional Epidemiology Research Center, Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, 287 Via Campi, 41125 Modena, Italy.ORCID 0000-0003-1490-5508
Marco VincetiCREAGEN-Environmental, Genetic and Nutritional Epidemiology Research Center, Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, 287 Via Campi, 41125 Modena, Italy.ORCID 0000-0002-0551-2473
Jessica MandrioliCenter for Neurosciences and Neurotechnology, Department of Biomedical, Metabolic, and Neural Sciences, University of Modena and Reggio Emilia, 287 Via Campi, 41125 Modena, Italy.ORCID 0000-0002-9244-9782
Annalisa ChiariNeurology Unit, Azienda Ospedaliero Universitaria di Modena, 71 Via del Pozzo, 41121 Modena, Italy.
Tommaso FilippiniCREAGEN-Environmental, Genetic and Nutritional Epidemiology Research Center, Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, 287 Via Campi, 41125 Modena, Italy.ORCID 0000-0003-2100-0344
Roberta BedinCenter for Neurosciences and Neurotechnology, Department of Biomedical, Metabolic, and Neural Sciences, University of Modena and Reggio Emilia, 287 Via Campi, 41125 Modena, Italy.
Manuela TondelliCenter for Neurosciences and Neurotechnology, Department of Biomedical, Metabolic, and Neural Sciences, University of Modena and Reggio Emilia, 287 Via Campi, 41125 Modena, Italy.
Cecilia SimoniniCenter for Neurosciences and Neurotechnology, Department of Biomedical, Metabolic, and Neural Sciences, University of Modena and Reggio Emilia, 287 Via Campi, 41125 Modena, Italy.ORCID 0000-0001-5456-2365
Giovanna ZamboniCenter for Neurosciences and Neurotechnology, Department of Biomedical, Metabolic, and Neural Sciences, University of Modena and Reggio Emilia, 287 Via Campi, 41125 Modena, Italy.ORCID 0000-0002-6133-3373
Misaki ShimizuLaboratory of Molecular Biology and Metabolism, Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai 980-8578, Japan.
Yoshiro SaitoLaboratory of Molecular Biology and Metabolism, Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai 980-8578, Japan.ORCID 0000-0002-0559-5889
University of Modena and Reggio Emilia · ITTohoku University · JPAzienda Ospedaliero-Universitaria di Modena · ITBoston University · US

Funding

Italian Ministry of Education, University and Research Dipartimenti di Eccellenza 2018-2022Mission Oriented Linea FOMO-Fondazione di Modena UNIMORE FAR 2020 and 2021
6 · The paper itself

Abstract

Selenoprotein P, a selenium-transporter protein, has been hypothesized to play a role in the etiology of neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS) and Alzheimer's dementia (AD). However, data in humans are scarce and largely confined to autoptic samples. In this case-control study, we determined selenoprotein P concentrations in both the cerebrospinal fluid (CSF) and the serum of 50 individuals diagnosed with ALS, 30 with AD, 54 with mild cognitive impairment (MCI) and of 30 controls, using sandwich enzyme-linked immunosorbent assay (ELISA) methods. We found a positive and generally linear association between CSF and serum selenoprotein P concentrations in all groups. CSF selenoprotein P and biomarkers of neurodegeneration were positively associated in AD, while for MCI, we found an inverted-U-shaped relation. CSF selenoprotein P concentrations were higher in AD and MCI than in ALS and controls, while in serum, the highest concentrations were found in MCI and ALS. Logistic and cubic spline regression analyses showed an inverse association between CSF selenoprotein P levels and ALS risk, and a positive association for AD risk, while an inverted-U-shaped relation with MCI risk emerged. Conversely, serum selenoprotein P concentrations were positively associated with risk of all conditions but only in their lower range. Overall, these findings indicate some abnormalities of selenoprotein P concentrations in both the central nervous system and blood associated with ALS and neurocognitive disorders, though in different directions. These alterations may reflect either phenomena of etiologic relevance or disease-induced alterations of nutritional and metabolic status.

Indexed as

Alzheimer DiseaseAmyotrophic Lateral SclerosisCognitive DysfunctionAmyloid beta-PeptidesBiomarkersCase-Control StudiesHumansPeptide FragmentsSelenoprotein Ptau ProteinsAmyloid beta-PeptidesBiomarkersPeptide FragmentsSelenoprotein Ptau Proteinsamyotrophic lateral sclerosisdementiamild cognitive impairmentseleniumselenoprotein P

Identifiers

PMID36077261
PMCPMC9456314
OpenAlexW4293773354

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.